Login
$CERO
$0.10 +$0.00 (0.0%) Close

$CERO SEC Filings

Filed On Filing
13 Nov 2026 QUARTERLY REPORT
07 Oct 2026 8-K: Entry into a Material Definitive Agreement

This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of October 6, 2026, is made by and among CERo Therapeutics Holdings, Inc., a Delaware corporation (“Seller”), and SRX Global Inc., a Delaware corporation formerly known as SRX He...

31 Aug 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT...

14 Aug 2026 PROSPECTUS SUPPLEMENT
14 Aug 2026 QUARTERLY REPORT
14 Aug 2026 SCHEDULE 13G/A
17 Jul 2026 PROSPECTUS SUPPLEMENT
17 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

13 Jul 2026 25-NSE
26 Jun 2026 PROSPECTUS SUPPLEMENT
26 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

29 May 2026 PROSPECTUS SUPPLEMENT
29 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Healt...

15 May 2026 PROSPECTUS SUPPLEMENT
15 May 2026 QUARTERLY REPORT
01 May 2026 PROSPECTUS SUPPLEMENT
01 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keysto...

01 May 2026 PROSPECTUS SUPPLEMENT
30 Apr 2026 AMENDMENT NO. 1 TO FORM 10-K
21 Apr 2026 Form 4: Francois Eric, Director

Granted 1,823,278 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support